Back to results
US 6,713,651 B1Granted
β2-adrenergic receptor agonists
AssigneeTheravance, Inc.
InventorsEdmund J. Moran, Seok-Ki Choi
Life of this patent
Estimating the term…
Abstract
Disclosed are multibinding compounds which are β2-adrenergic receptor agonists and are useful in the treatment and prevention of respiratory diseases such as asthma, and bronchitis. They are also useful in the treatment of nervous system injury and premature labor.
Claims9
A compound of Formula (II):
- wherein
- Ar1 and Ar3 are independently selected from the group consisting of aryl, heteroaryl, and heterocyclyl;
- Ar2 is selected from the group consisting of (a) phenylene, wherein W and X are attached at the 1,2-, 1,3- and 1,4-positions of the phenylene ring;
- (b) cyclohexylene optionally substituted with methyl, wherein W and X are attached at the 1,3- and 1,4-positions of the cyclohexylene ring;
- and piperazinylene, wherein W and X are attached at the 1,4-positions of the piperazinylene ring;
- X is a bond;
- and Q is selected from the group consisting of
- —(CH2)3—O—(CH2)6—NH—CH2—CH(OH)—,
- —O—(CH2)—CH(OH)—(CH2)—NH—(CH2)—CH(OH)—, and
- —NH—CH2—CH(OH)—CH2—O—;
- W is selected from the group consisting of a covalent bond, alkylene, and a substituted alkylene group wherein one or more of the carbon atoms in the alkylene group is optionally replaced by —O—;
- or a pharmaceutically acceptable salt thereof.
9 more elements
A compound of Formula (II):
- wherein
- Ar1 is selected from the group consisting of 4-hydroxy-3-hydroxymethylphenyl, 4-hydroxy-3-(HCONH—)phenyl, 3,5-dichloro-4-aminophenyl and
- Ar2 is phenylene, wherein W and X are attached at the 1,4-positions of the phenylene ring;
- Ar3 is selected from the group consisting of:
- wherein
- (i) Q is a covalent bond;
- and
- X is selected from the group consisting of
- —O—(CH2)4—,
- —(CH2)—(p-C6H10)—NH—CH2—CH(OH)—,
- —O—(p-C6H4)—NH—CH2—CH(OH)—,
- —O—(CH2)10—O—(p-C6H4)—(CH2)3—O—(CH2)6—NH—CH2—CH(OH)—, and
- —O—(CH2)6—O—(p-C6H4)—(CH2)3—O—(CH2)5—NH—CH2—CH(OH)—;
- or
- (ii) X is a bond;
- and Q is selected from the group consisting of
- —(CH2)3—O—(CH2)6—NH—CH2—CH(OH)—,
- —O—(CH2)—CH(OH)—(CH2)—NH—(CH2)—CH(OH)—, and
- —NH—CH2—CH(OH)—CH2—O—;
- W is —(CH2)6O—;
- or a pharmaceutically acceptable salt thereof.
18 more elements
A compound of Formula (II):
- wherein
- Ar1 is selected from the group consisting of phenyl, 4-hydroxyphenyl, 3,4-dihydroxyphenyl, 3,4-dichlorophenyl, 2-chloro-3,4-dihydroxyphenyl, 2-fluoro-3,4-dihydroxyphenyl, 2-chloro-3,5-dihydroxyphenyl, 2-fluoro-3,5-dihydroxyphenyl, 4-hydroxy-3-methoxyphenyl, 4-hydroxy-3-hydroxymethylphenyl, 4-hydroxy-3-(HCONH—)phenyl, 4-hydroxy-3-(NH2CO—)phenyl, 3-chlorophenyl, 2,5-dimethoxyphenyl, 4-(CH3SO2NH—)phenyl, 4-hydroxy-3-(CH3SO2CH2—)phenyl, 4-hydroxy-3-(CH3SO2NH—)phenyl, 4-hydroxy-3-(NH2CONH—)phenyl, 3,5-dichloro-4-aminophenyl,
- Ar2 is phenylene, wherein W and X are attached at the 1,4-positions of the phenylene ring;
- Ar3 is 4-hydroxy-3-hydroxymethylphenyl;
- wherein (i) Q is a covalent bond;
- and
- X is selected from the group consisting of
- —O—(CH2)4—,
- —(CH2)—(p-C6H10)—NH—CH2—CH(OH)—,
- —O—(p-C6H4)—NH—CH2—CH(OH)—,
- —O—(CH2)10—O—(p-C6H4)—(CH2)3—O—(CH2)6—NH—CH2—CH(OH)—, and
- —O—(CH2)6—O—(p-C6H4)—(CH2)3—O—(CH2)5—NH—CH2—CH(OH)—;
- or
- (ii) X is a bond;
- and Q is selected from the group consisting of
- —(CH2)3—O—(CH2)6—NH—CH2—CH(OH)—,
- —O—(CH2)—CH(OH)—(CH2)—NH—(CH2)—CH(OH)—, and
- —NH—CH2—CH(OH)—CH2—O—;
- W is —(CH2)6O—;
- or a pharmaceutically acceptable salt thereof.
17 more elements
A compound of Formula (II):
- wherein
- Ar1 is selected from the group consisting of aryl, heteroaryl, and heterocyclyl;
- Ar2 is selected from the group consisting of (a) phenylene, wherein W and X are attached at the 1,2-, 1,3- and 1,4-positions of the phenylene ring;
- (b) cyclohexylene optionally substituted with methyl, wherein W and X are attached at the 1,3- and 1,4-positions of the cyclohexylene ring;
- and piperazinylene, wherein W and X are attached at the 1,4-positions of the piperazinylene ring;
- Ar3 is selected from the group consisting of:
- wherein X is a bond;
- and Q is selected from the group consisting of
- —(CH2)3—O—(CH2)6—NH—CH2—CH(OH)—,
- —O—(CH2)—CH(OH)—(CH2)—NH—(CH2)—CH(OH)—, and
- —NH—CH2—CH(OH)—CH2—O—;
- W is selected from the group consisting of a covalent bond, alkylene, and a substituted alkylene group wherein one or more of the carbon atoms in the alkylene group is optionally replaced by —O—;
- or a pharmaceutically acceptable salt thereof.
10 more elements
Dependencies are inferred from the claim text.